Managing Director and CEO, John Kelly talks to the ASX about the inspiration behind Atomo, listing on the ASX during COVID-19 and why having the right advisors is crucial when you IPO. Watch the video and read the full interview here > ...
Managing Director and CEO, John Kelly talks to Ausbiz about Atomo’s expanded partnership with NG Biotech and securing exclusive rights to market and distribute the COVID-19 antibody test for Australia, NZ and parts of SE Asia. Watch the interview here > ...
Atomo secures exclusive rights for Australia, New Zealand and South East Asia¹ SYDNEY Australia, Thursday, 4 June 2020 – Atomo Diagnostics Limited (ASX: AT1) (Atomo) is pleased to announce it has expanded its existing COVID-19 rapid test partnership with NG Biotech, SAS (NG Biotech), which was...
Stockhead’s Tim Boreham discusses Atomo’s background and history and the benefits of its rapid blood test devices for a range of conditions including COVID-19. Read the full article > ...
In an article for Stockhead, Morgans senior analyst Scott Power discusses how Atomo’s rapid test for COVID-19 enabled it to list on the ASX in April. Read the full article > ...
Atomo CEO, John Kelly was interviewed by Peter Switzer on Switzer TV, talking about what makes Atomo’s devices unique, how they can be used to test for COVID-19 and the company’s upcoming key milestones. [embed]https://www.youtube.com/watch?v=XpLiQ6Ujq0c[/embed]...
An article in Bloomberg talks about Atomo’s rapid share price rise after its ASX listing in a broader piece on US IPOs amid COVID-19. Read the full article > ...
An article on the Kalkine Media website discusses Atomo’s ASX listing, its integrated rapid diagnostic test devices and agreement with NG Biotech for the supply of devices for the rapid blood-based testing of antibodies produced in response to COVID 19. Read the full article > ...
An article in WSJ.com looks at Atomo’s strong ASX debut and how its device could produce blood-test results in 15 minutes for COVID-19 testing. Read the full article > ...
An article by Damon Kitney in The Australian discusses how Atomo sharesclosed on their first day of trading on the Australian Securities Exchange at almost double their issue price as investors backed the rollout of its COVID-19 rapid testing equipment. Read the full article > ...
A feature in Biotech Daily talks about Atomo’s successful listing and the strong interest in the use of its integrated rapid test device for the testing of COVID-19 antibodies. Read the full article > ...
SYDNEY Australia 16 April 2020– Following an oversubscribed initial public offering and the first ASX virtual bell ringing listing, trading of shares in Australian rapid blood test company Atomo Diagnostics Limited (Atomo) will commence on the Australian Securities Exchange (ASX) today under the ticker code...
Founder and CEO John Kelly speaks to AAP about the company’s ASX debut and the company’s unique position to make a major impact within the COVID-19 environment. The article was syndicated across a range of national, metropolitan and regional press, 7 News.com.au, 9Finance and Yahoo7...
An article in Stockhead talks about how Atomo is focused on commercialising its rapid blood test devices for COVID-19. Read the full article here > ...
Atomo Diagnostics announced today that it has entered into a binding supply agreement with French diagnostics company, NG Biotech, SAS (NG Biotech), for the supply of Atomo’s integrated blood test devices to NG Biotech to use for its blood-based rapid test to detect COVID-19. Under the...
$30m Initial Public Offer closes oversubscribed SYDNEY Australia, 01 April 2020: Australian rapid blood test company Atomo Diagnostics Limited (ACN 142 925 684) said today it has entered into a binding supply agreement with French diagnostics company, NG Biotech, SAS (NG Biotech), for the supply of Atomo’s...
Founder and CEO John Kelly speaks to SBS World News about how Atomo Diagostics is using technology from its HIV rapid diagnostic tests (RDTs) to create a product that will test for Covid-19. [embed]https://vimeo.com/402583336[/embed] ...
Today, Founder and CEO of Atomo Diagnostics, John Kelly, was interviewed by Bloomberg on the subject of rapid diagnostic testing for coronavirus (COVID-19). John Kelly explained how Atomo is working with OEM partners in China, the USA, and Europe to bring to market rapid diagnostic tests...
Today, Atomo Diagnostics announced it was working with potential OEM customers to develop rapid self-tests for COVID-19 that could deliver results to patients in as little as 15 minutes, and be deployed in the field without the need for expensive laboratory equipment or extensive clinical...
SYDNEY Australia, 17 March 2020: Australian rapid blood test company Atomo Diagnostics Limited (ACN 142 925 6840) said today it was working with potential OEM customers to develop rapid self-tests for COVID-19 that could deliver results to patients in as little as 15 minutes, and be...